Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
420.00    -4.00 (-0.94%)
Bid:
420.00
Ask:
423.50
Spread: 3.50 (0.833%)
Market Cap: £206.56m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Director Declaration

27 Feb 2020 15:00

RNS Number : 3487E
Zotefoams PLC
27 February 2020
 

Zotefoams plc

(the 'Company')

 

 

 

 

 

Director Declaration

 

In accordance with Listing Rule 9.6.14, the Company announces that Steve Good, the non-executive Chairman of the Company, will resign from Dialight plc with effect from 31 March 2020.

 

 

 

Enquiries:

 

Lydia Harratt

Group Company Secretary

Zotefoams plc

020 8664 1600

 

27 February 2020

 

 

About Zotefoams plc:

 

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA, to customers worldwide.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell® Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® and ReZorce® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNSEEFSWESSESE
Date   Source Headline
17th Jan 200511:43 amRNSRule 2.10 Announcement
14th Jan 200510:19 amRNSStatement re Possible Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.